JoAnne Foody
Esperion CMO JoAnne Foody has departed, the company disclosed in an Aug. 5 SEC filing.
“We are grateful for her significant contributions to the company through the years and wish her the very best,” a spokesperson said.
Foody did not respond when contacted via LinkedIn.
Her exit marks the end of a three-year run at the company, after she joined in 2021 following more than four years at Johnson & Johnson. She began at J&J as the executive director of medical affairs for the cardiovascular unit, ascending to VP and head of data sciences for the cardiovascular, metabolism, retina and pulmonary hypertension therapeutic area.
Before joining the New Jersey pharma in 2016, Foody was the global director of scientific affairs for cardiovascular and metabolism at Merck.
Esperion has spent significantly less on R&D as it focuses on selling its approved cholesterol-lowering drugs, Nexletol and Nexlizet. Research and development
